Damora Therapeutics
DMRA
22 hedge funds and large institutions have $1.91M invested in Damora Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0.3% more ownership
Funds ownership: 14.59% → 14.89% (+0.3%)
15% less funds holding
Funds holding: 26 → 22 (-4)
38% less capital invested
Capital invested by funds: $3.09M → $1.91M (-$1.17M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$17.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$9.54K |
| 5 |
VF
Virtu Financial
New York
|
+$9.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$57K |
| 2 |
Jane Street
New York
|
-$20.4K |
| 3 |
BlackRock
New York
|
-$18.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$14.2K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$12.3K |
DMRA Hedge Fund Activity: Q2 2024 in Review
22 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q2 2024, worth a combined $1.91M — down 38% from $3.09M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DMRA and 4 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $106K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $57K sold.
- 22 institutional investors held Damora Therapeutics (DMRA) as of Q2 2024, down from 26 in Q1 2024.
- Funds reported $1.91M of Damora Therapeutics stock for Q2 2024, down 38% quarter-over-quarter.
- 4 funds opened new Damora Therapeutics positions in Q2 2024 and 8 closed out, a net change of -4 holders.
- The largest Damora Therapeutics buyer in Q2 2024 was Susquehanna International Group, an estimated $106K added.
- The largest Damora Therapeutics seller in Q2 2024 was Bridgeway Capital Management, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2024.